



California Medical Evaluators
11620 Wilshire Blvd. Suite 340
Los Angeles, CA 90025
Phone: 888.853.7944
Fax: 213.478.0550
info@calmedeval.com



Dr. Christopher Chow, MD, QME
Board Certified in Internal Medicine

Articulate, Board certified Internal Medicine Physician with more than 25 years of clinical expertise and 1 year of medical-legal expertise. Highly specialized in Internal Medicine.

EDUCATION

- **University of California at Berkeley, Berkeley, CA (1994)**
Bachelor of Arts, Molecular and Cellular Biology
- **New York Medical College, Valhalla, NY (1999)**
Doctor of Medicine, MD
- **Cedars-Sinai Medical Center, Los Angeles, CA (2000)**
Internship - Internal Medicine
- **Cedars-Sinai Medical Center, Los Angeles, CA (2002)**
Residency - Internal Medicine

PROFESSIONAL EXPERIENCE

- **Kerlan-Jobe Orthopedic Clinic, Head Research Coordinator (1994 – 1995)**
- **Medical Group of Beverly Hills, Resident Physician (1999 – 2002)**
- **Cedars Sinai Medical Center, Transitional Care Physician (1999 – 2002)**
- **Los Angeles Free Clinic, Urgent and primary care physician (1999 – 2002)**
- **Valley Clinical Trials, Primary Investigator and Co-Founder (2009 – Present)**
- **Private Practice in Internal Medicine, Attending Physician (2002 – Present)**

LICENSURE AND CERTIFICATION

- American Board of Internal Medicine
- California Board Certified Medical License
- Qualified Medical Evaluator (QME)

PROFESSIONAL MEMBERSHIPS

- American Board of Internal Medicine

RESEARCH & PUBLICATIONS

CANTOS, A Randomized, double-blind, placebo-controlled, event -driven trial of quarterly subcutaneous XXXXX in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

ATMOSPHERE, A multicenter, randomized, double-blind, parallel group, active- controlled study to evaluate the efficacy and safety of both aliskeren monotherapy and aliskeren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure

MK 0524-143A, A Phase 3 Multicenter, Double –Blind, Crossover Design Study to evaluate Lipid-Altering Efficacy and Safety of XXXXX XXX Combination Tablets in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

MK -0736, A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXXXX When Added to Ongoing Therapy with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) in patients with diabetes and hypertension

MK-0431-180, A Phase III, Multicenter, Randomized, Open-label Study Comparing the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination with Liraglutide in Patients With Type 2 Diabetes Mellitus

BEGIN, NN1250-3579, 3724, 3948 Randomized, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety XXXX and Insulin Glargine, Both Injected Daily in Combination with Oral Anti-diabetic Drugs (OADs), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs and Qualifying More Intensified Treatment

EXSCEL, A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

ACCORD, Action to Control Cardiovascular Risk in Diabetes

TECOS, Trial to Evaluate Cardiovascular Outcomes with Sitigliptin, A Randomized, Placebo Controlled Clinical Trial in Type II Diabetics with inadequate glucose control.